CHRS News and Press, Coherus BioSciences Inc. From 12/08/23

2023-12-08 08:27:04 ET More on pr-market losers $ stocks. Aditxt appoints Ernie Lee as CEO of its wholly-owned subsidiary, Pearsanta IPO Roundup: WeBuy Global, Maison Solutions and more Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earn...

2023-12-07 18:04:47 ET More on Coherus BioSciences Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript For further details see: ...

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the company to pursue other opportunities. Mr. Stilwell’s last day of employment with Cohe...

– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support continued evaluation of casdozokitug in combination with anti-PD-1 antibody tr...

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...

2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...

2023-11-28 13:35:38 ET More on Coherus BioSciences Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript Coherus stock rises as Ba...

– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in...

2023-11-20 09:33:00 ET Summary For the week, the S&P 500 was up 2.2%. After three consecutive up weeks, we are now just 1.6% below the 2023 high-water mark, set on July 31. The best performer last week was the small-cap Russell 2000, as investors sought bargains among the asse...

2023-11-17 17:01:57 ET Gainers: Cogent Biosciences ( COGT ) +3% . Erasca ( ERAS ) +3% . Vigil Neuroscience ( VIGL ) +3% . 2seventy  ( TSVT ) +2% . Twist Biosciences ( TWST ) +2% . Losers: Nkarta ( NKTX ) -5% ...